Product Description
BSI-04702 is an anti-TROP2 humanized monoclonal antibody created by Biosion's proprietary SynTracer™ internalization TROP2 is highly expressed in various cancer cells, such as pancreatic, gastric, lung, colorectal cancer cells, and its overexpression is associated with poor survival in patients with solid tumors. In Dec 2021, Biosion licensed ex-Greater China rights of BSI-04702 to OBI Pharma. (Sourced from: https://www.biosion.com/pipeline)
Mechanisms of Action: TROP2 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biosion
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|